Using an anti inflammatory eye implant (Ozurdex) to help improve surgical outcomes in patients with scar tissue (PVR) on the retina

Registry ID

EUCTR2011-004498-96

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Moorfields Eye Hospital

Start date

2011-11-18

Completion date

2015-02-17

Last update

2026-08-16

Conditions

• Proliferative Vitreoretinopathy

Summary

Does the use of an additional anti inflammatory agent (ozurdex) given at the time of surgery in patients with established PVR (scar tissue on the retina)result in an improved surgical outcome at 6 months after the surgery?

Locations

• , , UK

Related clinical trials

• Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.
• Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
• Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

View on source registry